The news: Novo Nordisk applied for FDA approval of a higher-dose version of its weight loss drug Wegovy using a special FDA review pathway for a faster decision.

• The proposed 7.2 mg dose showed an average 20.7% weight loss in trials, while the current highest-dose Wegovy at 2.4 mg resulted in 15% weight loss.
• 33.2% of patients on Wegovy 7.2 mg achieved average weight loss of 25% compared to 16.7% for patients on 2.4 mg and 0% for those taking a placebo, per Novo’s STEP UP trial.
• Novo is using its fast-track Commissioner’s National Priority Voucher (CNPV) granted earlier this month to speed the higher dose review time to 1 to 2 months.

Why it matters: Novo lost its GLP-1 weight loss market share lead to Eli Lilly’s Zepbound, thanks in part to data that showed Wegovy is not as effective as Zepbound.

• In a head-to-head test of Zepbound versus Wegovy published in May, Zepbound achieved an average 20.2% weight loss compared with 13.7% for Wegovy in 72 weeks.
• Novo cut its full-year forecast three times this year, and attributed it to slower-than-expected sales of its GLP-1 drugs Wegovy and Ozempic.
• Lilly took the US GLP-1 market share lead in January, and by September accounted for 58% of total prescriptions compared to Novo’s 42%, per IQVIA data shared in Lilly’s Q3 presentation.

Implications for weight loss drugmakers: Novo’s and Lilly's drugs have set a very high bar—over 20% weight loss—making it the new benchmark for success. This high standard means more than 100 competing drug candidates (per STAT’s obesity drug tracker) may struggle to prove their value if they show weaker results.

Novo’s move also intensifies its rivalry with Lilly ahead of both of their expected oral GLP-1 launches in 2026. Next-generation weight loss pills are expected to capture 25% of the anti-obesity drug market by 2030, creating a race to define convenience, adherence, and pricing advantages. Although both drugmakers have already negotiated lower direct-to-consumer pricing with the Trump administration, the competitive market means targeted discounts and new user incentives are likely as each one looks to gain traction in the expanding category.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.